Tier 2 — strong

Does quercetin and vitamin C improve exercise performance, muscle damage, and body composition in male athletes?

Gholamreza Askari, Reza Ghiasvand, Jahangir Karimian, Awat Feizi, Zamzam Paknahad, Gholamreza Sharifirad, Maryam Hajishafiei
Journal of research in medical sciences : the official journal of Isfahan University of Medical Sciences 2012 17(4):328-31

Bibliography

PubMed
PMID 23267392
PubMed Central
PMC3526124
Funding
Funding was not specified in the indexed record or the disclosure metadata available for this entry.
Competing interests
Reported disclosure: None declared

Study snapshot

DesignRandomized double-blind placebo-controlled four-arm athlete trial
ModelHuman intervention research
Sample60 male students
InterventionQuercetin 500 mg/day, vitamin C, their combination, or placebo
Duration8 weeks
EndpointsExercise performance or recovery

What the study showed, in plain terms

Published in 2012, this source examined exercise and recovery. Design: Randomized double-blind placebo-controlled four-arm athlete trial. Sample/model: 60 male students. The exposure or intervention was Quercetin 500 mg/day, vitamin C, their combination, or placebo. Follow-up or treatment period: 8 weeks.

Between-group differences in exhaustion time, muscle-damage indices, and body fat were not significant.

The conclusion emphasizes some within-group changes despite null comparative results. Related athlete publications likely share participants and use differing dose descriptions.

Continue with Quercetin Data Center

For topic-level interpretation, read Quercetin for Exercise: Performance, Recovery and Muscle. This is a related guide; the citation panel separately identifies articles that directly cite this paper.

Key findings

  • Between-group differences in exhaustion time, muscle-damage indices, and body fat were not significant.
  • The recorded outcome domains were Exercise performance or recovery.
  • The result applies to the tested exposure: Quercetin 500 mg/day, vitamin C, their combination, or placebo; 8 weeks.

What this study can and cannot tell us

  • The conclusion emphasizes some within-group changes despite null comparative results. Related athlete publications likely share participants and use differing dose descriptions.
  • An individual controlled trial must be interpreted alongside its comparator, sample size, endpoint selection and independent replication. It does not validate a different commercial formulation or a general longevity claim.
  • Companion or correction records are linked below. They should not be counted automatically as independent replications; see the individual source notes for the relationship.
  • Source basis: Source check: PubMed abstract and indexed metadata; full methods were not independently confirmed for this entry. Missing method details, funding information or participant denominators are not inferred.

Editorial review

Reviewed by the Biohack Blueprint research team

Last verified